A) Risperdal B) Geodon C) Prolixin D) Zyprexa
A) Abilify B) Zyprexa C) Invega D) Clozaril
A) Abilify B) Invega C) Seroquel D) Zyprexa
A) Abilify B) Zyprexa C) Risperdal D) Seroquel
A) Seroquel B) Geodon C) Risperdal D) Abilify
A) Ziprasidone B) Clozapine C) Olanzapine D) Quetiapine
A) Paliperidone B) Ziprasidone C) Risperidone D) Aripriprazole
A) Geodon B) Seroquel C) Risperdal D) Clozaril
A) Aripiprazole B) Clozapine C) Paliperidone D) Ziprasidone
A) Olazapine B) Quetiapine C) Risperdone D) Paliperidone
A) Clozapine and Aripiprazole B) Clozapine and Risperadone C) Risperidone and Paliperidone D) Aripiprazole and Paliperidone
A) 2-5 B) 1-3 C) 4-5 D) 1
A) 18 B) 12 C) 24 D) 6
A) FALSE B) TRUE
A) Foster patients' medication compliance B) Prevent relapse into another psychotic episode C) Develop more adaptive coping skills D) Minimize side effects of medication
A) directly after discontinuation of medication B) several weeks after discontinuation of medication C) six months after discontinuation of medication D) one year after discontinuation of medication
A) Symmetrel B) Thorazine C) Artane D) Clozaril
A) enhanced efficacy in treatment-resistant patients B) increased effectiveness for positive, negative, and disorganized symptoms C) tardive dyskinesia more common D) weight gain more common
A) Prochlorperazine B) Risperidone C) Haloperiodol D) Clozapine
A) Stimulants B) Anxiolitics C) Alcohol D) Anticonvulsants
A) Beta blockers B) Merperidine C) Halperiodol D) Alcohol
A) Anticonvulsants B) Nicotine C) Antacids D) Beta blockers
A) Tricyclic antidepressants B) SSRIs C) Beta blockers D) Alcohol
A) FALSE B) TRUE
A) Alcohol use B) Male gender C) Tobacco use D) Drug holidays
A) FALSE B) TRUE
A) High potency antipsychotic drugs present greater risk for the development of tardive dyskinesia. B) All antipsychotic drugs but Clozapine present a significant risk for the development of tardive dyskinesia. C) Classic antipsychotic medications present less risk for the development of tardive dyskinesia than atypical antipsychotic medications. D) The more frequent the dose of the antipsychotic medication, the greater the risk for the development of tardive dyskinesia.
A) Ataxia B) Akinesia C) Acute dystonia D) Akathesia
A) Agranulocytosis B) Neuroleptic Malignant Syndrome C) Postural hypotension D) Gynecomastia
A) TRUE B) FALSE
A) TRUE B) FALSE
A) block D2 receptors in the pituitary gland and inhibit prolactin secretion. B) block D2 receptors in the pituitary gland and decrease prolactin secretion. C) agonize the normal dopamine-mediated inhibition of prolactin release. D) antagonize the normal dopamine-mediated inhibition of prolactin release.
A) neuroendocrine changes B) molecular structure C) hungry hungry hippos D) receptor binding and DA turnover
A) Phenothiazines B) Thioxanthenenes C) Sleepykoaladones D) Butyrophenones
A) Weak; high; lower B) Potent; low; lower C) Weak; high; higher D) Potent; low; higher
A) Delusions B) Formal thought disorder C) Hallucinations D) Anhedonia
A) All of the above B) Endocrine disorders C) Metabolic disorders D) Neurological disorders E) Autoimmune diseases
A) All of the above B) Stimulants C) Opioids D) Hallucinogens E) Alcohol
A) TRUE B) FALSE
A) disorganized symptoms of Schizophrenia. B) positive symptoms of Schizophrenia. C) All of the above. D) negative symptoms of Schizophrenia.
A) blocking post-synaptic dopamine receptors and/or inhibiting dopamine reuptake. B) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine reuptake. C) blocking post-synaptic dopamine receptors and/or inhibiting dopamine release. D) blocking pre-synaptic dopamine receptors and/or inhibiting dopamine release.
A) the drug increases the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. B) the drug reduces the normal dopamine-mediated activity in the striatum, which then reduces the cholinergic response that is normally inhibited by dopamine. C) the drug increases the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine. D) the drug reduces the normal dopamine-mediated activity in the striatum, which then enhances the cholinergic response that is normally inhibited by dopamine.
A) increased rates of firing B) increased release of dopamine C) increased tap dancing D) increased rates of synthesis
A) piperideines B) aliphatics C) thioxanthenes D) piperazines
A) galactorrhea B) menstrual irregularity C) genecomastia D) all of the above
A) Inapsine (droperiodol) B) Cogentin (benztropine) C) Symmetrel (amantadine) D) Benadryl (diphenhydramine) E) Artane (trihexphenidyl)
A) TRUE B) FALSE
A) comparative lack of EPS B) superior impact on positive symptoms C) actual impact at the biological level D) polypharmacy
A) Abilify B) Haldol C) Clozaril D) Invega
A) Seroquel B) Geodon C) Risperdal D) Clorazil |